Literature DB >> 729602

Electrocardiographic and hemodynamic effects of tocainide (W-36095) in man.

K Swedberg, J Pehrson, L Rydén.   

Abstract

Tocainide is a new antiarrhythmic drug with a chemical structure related to that of lidocaine. In the present study, healthy volunteers were investigated after infusion of tocainide 450 mg over 45 min. In nine subjects His bundle electrograms, sinus recovery time and ventricular effective refractory periods were recorded. No major changes were seen. In eight cases the hemodynamic effects at rest and during exercise were studied. No significant circulatory effects were observed. No clinically important side-effects were noted.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 729602     DOI: 10.1007/bf00560253

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients.

Authors:  K I Lie; H J Wellens; F J van Capelle; D Durrer
Journal:  N Engl J Med       Date:  1974-12-19       Impact factor: 91.245

2.  Antiarrhythmic and circulatory effects of Astra W36095, a new lidocaine-like agent.

Authors:  D J Coltart; T B Berndt; R Kernoff; D C Harrison
Journal:  Am J Cardiol       Date:  1974-07       Impact factor: 2.778

3.  Catheter technique for recording His bundle activity in man.

Authors:  B J Scherlag; S H Lau; R H Helfant; W D Berkowitz; E Stein; A N Damato
Journal:  Circulation       Date:  1969-01       Impact factor: 29.690

4.  Electrophysiological effects of the antiarrhythmic agent QX-572 in the human heart with special reference to rate-induced changes in effective refractory periods.

Authors:  L Rydén; B Olsson; J Kvasnicka
Journal:  Cardiovasc Res       Date:  1975-01       Impact factor: 10.787

5.  The effect of therapeutic doses of lidocaine hydrochloride on the effective refractory period of the right ventricle in man.

Authors:  S B Olsson; R Harper; L Rydén; W A Hilmy
Journal:  Cardiovasc Res       Date:  1975-09       Impact factor: 10.787

6.  Clinical efficacy and pharmacokinetics of a new orally effective antiarrhythmic, tocainide.

Authors:  R A Winkle; P J Meffin; J W Fitzgerald; D C Harrison
Journal:  Circulation       Date:  1976-12       Impact factor: 29.690

  6 in total
  5 in total

Review 1.  Tocainide. A review of its pharmacological properties and therapeutic efficacy.

Authors:  B Holmes; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-08       Impact factor: 9.546

2.  Successuful treatment of paramyotonia congenita (Eulenburg): muscle stiffness and weakness prevented by tocainide.

Authors:  K Ricker; A Haass; R Rüdel; R Böhlen; H G Mertens
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-03       Impact factor: 10.154

Review 3.  New antiarrhythmic drugs.

Authors:  P F Nestico; J Morganroth; L N Horowitz
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

4.  Stereoselective disposition of RS-tocainide in man.

Authors:  K J Hoffmann; L Renberg; C Bäärnhielm
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jul-Sep       Impact factor: 2.441

Review 5.  Clinical electrophysiologic effects of flecainide acetate.

Authors:  D Mehta; A J Camm; D E Ward
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.